<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: It was the main aim of this study to obtain data on the epidemiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>- and not <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defined <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in HIV-positive persons, the results to provide an epidemiological overview and to be the basis for further research initiatives </plain></SENT>
<SENT sid="1" pm="."><plain>Additionally it sought to gain an impression of the realities of treatment of patients with HIV-associated <z:mp ids='MP_0002018'>malignant tumors</z:mp> in Germany </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Over a period of 3 years (from the beginning of 2000 to the end of 2002) data were retrospectively collected on the incidence of <z:mp ids='MP_0002018'>malignant tumors</z:mp> in HIV-positive patients </plain></SENT>
<SENT sid="3" pm="."><plain>A questionnaire was sent to <z:hpo ids='HP_0000001'>all</z:hpo> members of the German Working Party of Physicians in Private Practice Treating HIV-Infected Patients, <z:hpo ids='HP_0000001'>all</z:hpo> members of the Association of Haematologists and Oncologists in Private Practice, and <z:hpo ids='HP_0000001'>all</z:hpo> out-patient HIV clinics in Germany </plain></SENT>
<SENT sid="4" pm="."><plain>The questionnaires were sent to a total of 949 practices/clinics </plain></SENT>
<SENT sid="5" pm="."><plain>The data were collected on <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>- and not-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defined <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> and <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>- and not-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defined solid <z:mp ids='MP_0002018'>malignant tumors</z:mp> in HIV-positive patients, as well as on time of diagnosis of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> treatment and response to treatment </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: 380 data sets on 376 patients of 50 practices/clinics were included in the analysis (four patients had two <z:mp ids='MP_0002018'>malignant tumors</z:mp>) </plain></SENT>
<SENT sid="7" pm="."><plain>180 malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (47%) were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defined: 89 <z:hpo ids='HP_0100726'>Kaposi's sarcomas</z:hpo>, 82 aggressive B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 9 invasive cervical <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>The aggressive B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> consisted of 19 cases of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 8 of <z:e sem="disease" ids="C0017531" disease_type="Disease or Syndrome" abbrv="GLNH|AFLH">Castleman's disease</z:e> and 12 of primary cerebral malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Of the 200 (52.6%) not-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defined <z:mp ids='MP_0002018'>malignant tumors</z:mp> 133 were 133 solid <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, 40 of them anal <z:mp ids='MP_0002038'>carcinoma</z:mp> (20% of <z:hpo ids='HP_0000001'>all</z:hpo> not-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defined <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>) and 67 haematological <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, 22 of these Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (11.0% of <z:hpo ids='HP_0000001'>all</z:hpo> not-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defined <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>) </plain></SENT>
<SENT sid="10" pm="."><plain>The incidence of anal <z:mp ids='MP_0002038'>carcinoma</z:mp> is estimated to be 34 (95% CI 24-470) per 100 000 patient-years, that of Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 19 (95% CI 12-28) per 100 000 patient-years </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: This study indicates that over a period of 3 years there was a very high incidence of not-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defined <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Of special note is the high incidence of anal <z:mp ids='MP_0002038'>carcinoma</z:mp> and Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, compared with their incidence among the entire German population </plain></SENT>
</text></document>